Romosozumab (Evenity®)
Romosozumab (Evenity®) is reimbursed on the High Tech Arrangement from 1st November 2024. A Managed Access Protocol (MAP) is in place for romosozumab for the treatment of severe osteoporosis. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of romosozumab for the treatment of severe osteoporosis under the High Tech Arrangement.
Applications for reimbursement approval for romosozumab for the treatment of severe osteoporosis under the High Tech Arrangement will only be considered from consultants with specialist registration with the Irish Medical Council in a specialism relevant to the management of osteoporosis (e.g. endocrinology, gerontology, rheumatology), and who have agreed to the terms of the MAP and been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
A copy of the MAP for romosozumab can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.